INFlUENCE OF ARGININE METABOLITES ON HUMAN TUMOR CELL VIABILITY UPON ARGININE DEPRIVATION IN VITRO

Y. V. Kurlishchuk, B. O. Vynnytska-Myronovska, Y. P. Bobak, O. V. Stasyk


DOI: http://dx.doi.org/10.30970/sbi.0502.148

Abstract


In human organism arginine is necessary not only for protein synthesis but it also serves as a precursor for a number of important biologically active substances that influence cell growth and viability. These substances include such arginine metabolites as polyamines, nitric oxide, agmatine, ornithine and urea. It is known that in vitro tumor cells substantially differ in the level of sensitivity to arginine deprivation, which is reflected in the dynamics of apoptotic manifestations under these conditions. Identification of the molecular reasons of this phenomenon is important for optimization of the regimes of arginine deprivation-based anticancer enzymotherapy. One of possible reasons of the various level of sensitivity of tumor cells to arginine deprivation may reside in differences in their susceptibility to arginine catabolites withdrawal. Therefore, we aimed to investigate the effect of exogenous arginine metabolites (polyamines putrescine and spermine, as well as agmatine, nitric oxide, ornithine and urea) under arginine deprived conditions on viability and proliferative potential of two human cancer cell lines (A549 lung carcinoma and HepG2 hepatocarcinoma) that differ in the level of sensitivity to arginine depletion. It was revealed that none of the studied arginine catabolite affected cancer cell viability and proliferative potential in arginine-free medium, independently of the level of their sensitivity to arginine starvation. Thus, despite the complexity and versatility of arginine metabolic networks, the depletion of metabolites of this amino acid is not a key reason that determines differences in cell response to arginine deprivation. Therefore, identification of signaling mechanisms that underlie apoptosis induction in cancer cells upon arginine starvation needs to be further elucidated.


Keywords


arginine starvation, arginine metabolites, putrescine, spermine, agmatine, nitric oxide, ornithine, urea

References


1. Arndt M.A., Battaglia V., Parisi E. et al. The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis. Am. J. Physiol. Cell Physiol, 2009; 296(6): 1411-1419.
https://doi.org/10.1152/ajpcell.00529.2008
PMid:19321739 PMCid:PMC2692420

2. Basuroy U.K., Gerner E.W. Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J. Biochem, 2006; 139(1): 27-33.
https://doi.org/10.1093/jb/mvj022
PMid:16428316

3. Bobak Y.P., Vynnytska B.O., Kurlishchuk Y.V. et al. Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes. Cell Biol. Int, 2010; 34(11): 1085-1089.
https://doi.org/10.1042/CBI20100451
PMid:20653567

4. Cheng P.N., Lam T.L., Lam W.M. et al. Pegylated recombinant human arginase (rhArg-peg5000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res, 2007; 67(1): 309-317.
https://doi.org/10.1158/0008-5472.CAN-06-1945
PMid:17210712

5. Glazer E.S., Piccirillo M., Albino V. et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J. Clin. Oncol, 2010; 28(13): 2220-2226.
https://doi.org/10.1200/JCO.2009.26.7765
PMid:20351325

6. Hill J.M., Roberts J., Loeb E. et al. L-asparaginase therapy for leukemia and other malignant neoplasms: remission in human leukemia. JAMA, 1967; 202(9): 882-888.
https://doi.org/10.1001/jama.1967.03130220070012
PMid:5234350

7. Kuo M.T., Savaraj N., Feun L.G. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget, 2010; 1(4): 246-251.
https://doi.org/10.18632/oncotarget.135
PMid:21152246 PMCid:PMC2998341

8. Morris S.M. Arginine: beyond protein. Am. J. Clin. Nutr, 2006; 83(2): 508S-512S.
https://doi.org/10.1093/ajcn/83.2.508S
PMid:16470022

9. Morris S.M. Arginine metabolism: boundaries of our knowledge. J. Nutr, 2007; 137(6): 1602S-1609S.
https://doi.org/10.1093/jn/137.6.1602S
PMid:17513435

10. Nakauchi T., Ando A., Ueda-Yamada M. et al. Prevention of ornithine cytotoxicity by nonpolar side chain amino acids in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci, 2003; 44(11): 5023-5028.
https://doi.org/10.1167/iovs.03-0403
PMid:14578430

11. Scott L., Lamb J., Smith S., Wheatley D.N. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br. J. Cancer, 2000; 83(6): 800-810.
https://doi.org/10.1054/bjoc.2000.1353
PMid:10952786 PMCid:PMC2363527

12. Tan Y., Xu M., Hoffman R.M. Broad selective efficacy of recombinant methioninase and polyethylene glycol-modified recombinant methioninase on cancer cells in vitro. Anticancer Res, 2010; 30(4): 1041-1046.

13. Vynnytska B.O., Mayevska O.M., Kurlishchuk Y.V. et al. Canavanine augments proapoptotic effects of arginine deprivation in cultured human cancer cells. Anticancer Drugs, 2011; 22(2): 148-157.
https://doi.org/10.1097/CAD.0b013e32833e0334
PMid:20717004

14. Wheatley D.N. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Semin. Cancer Biol, 2005; 15(4): 247-253.
https://doi.org/10.1016/j.semcancer.2005.04.002
PMid:15886013

15. Wheatley D.N., Philip R., Campbell E. Arginine deprivation and tumour cell death: Arginase and its inhibition. Mol. Cell Biochem, 2003; 244():177-185.
https://doi.org/10.1007/978-1-4615-0247-0_26
PMid:12701828

16. Wink D.A., Vodovotz Y., Laval J. et al. The multifaceted roles of nitric oxide in cancer. Carcinogenesis, 1998; 19(5): 711-721.
https://doi.org/10.1093/carcin/19.5.711
PMid:9635855

17. Wu G., Morris S.M. Arginine metabolism: nitric oxide and beyond. Biochem. J, 1998; 336(1): 1-17.
https://doi.org/10.1042/bj3360001
PMid:9806879 PMCid:PMC1219836

18. Zou C., Vlastos A.T., Yang L. et al. Effects of difluoromethylornithine on growth inhibition and apoptosis in human cervical epithelial and cancerous cell lines. Gynecol. Oncol, 2002; 85(2): 266-273.
https://doi.org/10.1006/gyno.2002.6599
PMid:11972386


Refbacks

  • There are currently no refbacks.


Copyright (c) 2011 Studia biologica

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.